🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

Washington state's abortion pill stockpile is insurance against Trump win, governor says

Published 09/25/2024, 06:07 AM
Updated 09/25/2024, 12:56 PM
© Reuters. Washington Governor Jay Inslee stands on the tarmac while traveling to an event in Walla Walla, Washington, U.S., September 18, 2024. REUTERS/Matt Mills McKnight

By Matt McKnight and Joseph Ax

OLYMPIA, Washington (Reuters) - Washington state's first-in-the-nation stockpile of abortion drugs will serve as insurance against future lawsuits seeking to ban the procedure nationwide or a second presidential term for Republican Donald Trump, Governor Jay Inslee said.

Last year, with a federal lawsuit seeking to restrict access to abortion medication nationwide, Inslee, a Democrat, ordered the state's Department of Corrections to use its pharmacy license to purchase 30,000 doses of the abortion drug mifepristone.

The U.S. Supreme Court rejected the case in June, keeping mifepristone on the market. But the ruling left the door open to further legal challenges, and abortion rights advocates warn that the medication remains at risk.

In an interview with Reuters, Inslee, 73, said the state would maintain its stockpile pending the result of the Nov. 5 presidential election between Trump and Democratic U.S. Vice President Kamala Harris.

"The Supreme Court decision was not definitive in protecting mifepristone," Inslee told Reuters at the governor's mansion in Olympia. "This is a long-term threat. Those who want to take away reproductive health for women, they're not going to stop last week, this week or next week. It is a multi-decade effort."

Trump has sometimes taken a muddled position on abortion, including mifepristone, commonly prescribed as part of a two-drug regimen to end early pregnancies. In August, the former president suggested he might be open to directing the Food and Drug Administration to revoke access to the drug if he wins the election, though his campaign later said he would not seek to do so.

Trump has touted his role in appointing three Supreme Court appointees who helped drive the court's majority decision in 2022 to eliminate a nationwide right to abortion after five decades.

"You just can't trust him when it comes to women's reproductive health," said Inslee, who is leaving office in January after serving 12 years as governor.

© Reuters. Washington Governor Jay Inslee stands on the tarmac while traveling to an event in Walla Walla, Washington, U.S., September 18, 2024. REUTERS/Matt Mills McKnight

The doses are enough to supply the state's abortion patients for an estimated three years. Washington has seen the number of out-of-state women traveling there for abortions increase since 2022, when numerous states - including nearby Idaho - implemented bans in the wake of the Supreme Court's decision.

Harris and other Democrats have made abortion a central campaign issue this year. A majority of Americans say abortion should be legal in most or all cases, according to Reuters/Ipsos polling.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.